Skip to content

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

PDCD4-driven steatosis via the HNF4A/GK axis is attenuated by the natural compound isosinensetin.

BACKGROUND Programmed cell death factor 4 (PDCD4) has been implicated in various metabolic disorders. However, its role and underlying mechanisms in metabolic dysfunction-associated steatotic liver disease (MASLD) have not been fully elucidated. PURPOSE This study aimed to define the role of PDCD4 in hepatic steatosi...

Xiao-Na Cheng, Kai-Kai Lu, Lu-Yun Yang et al. · 0 citations
Sep 2026

Cardiovascular-kidney-metabolic syndrome and the risk of liver-related and cardiovascular events across the steatotic liver disease spectrum.

A higher CKM stage is associated with an increased long-term risk of MACEs and LREs across the SLD spectrum, and obesity and hypertension are the primary contributors to both outcomes, and diabetes additionally contributes to LREs.

Qiong-Yue Fan, Li-You Lian, Tian-Yi Xia et al. · 0 citations
Aug 2026

Activation of the KPNA2-mediated nuclear import of PPARα by KIF13B mitigates alcohol-associated liver steatosis.

This study identifies KIF13B as a novel regulator of hepatic lipid homeostasis in ALD via the KIF13B-KPNA2-PPARα axis, enhancing KPNA2 mediated nuclear import, particularly in combination with PPARα activation, represents a promising therapeutic strategy for ALD.

Kai-Kai Lu, Si Mei, Lian-Xing Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.